{"id":"NCT01028027","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis","officialTitle":"A Clinical Safety and Efficacy Evaluation of ZyletÂ® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-02","completion":"2010-03","firstPosted":"2009-12-09","resultsPosted":"2011-09-15","lastUpdate":"2012-02-28"},"enrollment":357,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Conjunctivitis","Keratitis","Blepharitis"],"interventions":[{"type":"DRUG","name":"Loteprednol and tobramycin","otherNames":["Zylet"]},{"type":"DRUG","name":"Tobramycin and dexamethasone","otherNames":["Tobradex"]}],"arms":[{"label":"Loteprednol and tobramycin","type":"EXPERIMENTAL"},{"label":"Tobramycin and dexamethasone","type":"ACTIVE_COMPARATOR"}],"summary":"This study is to evaluate the safety and efficacy of loteprednol etabonate \\[LE\\] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).","primaryOutcome":{"measure":"Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population","timeFrame":"Baseline, Day 15","effectByArm":[{"arm":"Loteprednol and Tobramycin","deltaMin":-11.63,"sd":4.56},{"arm":"Tobramycin and Dexamethasone","deltaMin":-12.41,"sd":4.71}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Singapore"]},"refs":{"pmids":["22256909"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":177},"commonTop":["Increased IOP"]}}